Implantable intrathecal pumps for chronic pain: Highlights and updates

Croatian Medical Journal

Volumn 48, Issue 1, 2007, Pages 22-34

  Knight, Karen H ^a,c   Brand, Frances M ^a   Mchaourab, Ali S ^a   Veneziano, Giorgio ^b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cleveland FES Centre   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BACLOFEN; BUPIVACAINE; CEFAZOLIN; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; CLONIDINE; COCAINE; FENTANYL; HYDROMORPHONE; METHADONE; MIDAZOLAM; MORPHINE; MORPHINE SULFATE; OMEGA CONOTOXIN MVIIA; OPIATE; VANCOMYCIN;

ANALGESIA; BLEEDING; BRAIN INJURY; CATHETER OCCLUSION; CHRONIC PAIN; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG SUBSTITUTION; FIBROSIS; FRACTURE; HEART ARRHYTHMIA; HUMAN; HYGROMA; HYPOGONADOTROPIC HYPOGONADISM; HYPOTENSION; INFECTION; INFLAMMATION; LIBIDO; LIQUORRHEA; LITERATURE; MEDICATION ERROR; MEDLINE; MINIPUMP; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PARESTHESIA; PATIENT SELECTION; PERIPHERAL EDEMA; REBOUND; REVIEW; SEDATION; SEROMA; SIDE EFFECT; SURGICAL TECHNIQUE; TREATMENT OUTCOME; URINE RETENTION;

ANALGESICS; ANALGESICS, OPIOID; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT DESIGN; EQUIPMENT SAFETY; FEMALE; FORECASTING; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MALE; PAIN MEASUREMENT; PAIN, INTRACTABLE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847240102     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Kalb C. Taking a new look at pain. Newsweek. May 19, 2003. p. 43.
2. Miller RD. Miller's anesthesia. 6th edition. Philadelphia, PA: Churchill Livingstone; 2004.
3. Weiner K. Pain issues: Pain is an epidemic. American Academy of Pain Management. Available from: http://www. aapainmanage.org. Accessed: January 26, 2007.
4. Loeser JD, Butler SH, Chapman CR, Turk DC, editors. Bonica's management of pain. Philadelphia: Lippincott Williams & Wilkins; 2001.
5. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040-9.
6. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10:127-35.
7. Bier A. Attempts over Cocainisirung of the Ruckenmarkers [in German]. Deutsche Zeitschrift für Chirurgie. 1899;51:361-9.
8. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516-20.
9. Kitagawa O. On spinal anesthesia with cocaine. Japan society of surgery. 1901;3:185-91.
10. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011-4.
11. Yaksh TL, Rudy TA. Analgesia mediated by a direct spinal action of narcotics. Science. 1976;192:1357-8.
12. Atweh SF, Kuhar MJ. Autoradiographic localization of opiate receptors in rat brain. I. Spinal cord and lower medulla. Brain Res. 1977;124:53-67.
13. Basbaum AI, Clanton CH, Fields HL. Opiate and stimulus-produced analgesia: functional anatomy of a medullospinal pathway. Proc Natl Acad Sci U S A. 1976;73:4685-8.
14. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50:149-51.
15. Alper MH. Intrathecal morphine: a new method of obstetric analgesia? Anesthesiology. 1979;51:378-9.
16. Coombs DW, Maurer LH, Saunders RL, Gaylor M. Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain control. J Clin Oncol. 1984;2:1414-20.
17. Krames ES, Gershow J, Glassberg A, Kenefick T, Lyons A, Taylor P, et al. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer. 1985;56:696-702.
18. Onofrio BM, Yaksh TL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg. 1990;72:200-9.
19. Follett KA, Hitchon PW, Piper J, Kumar V, Clamon G, Jones MP. Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain. 1992;49:21-5.
20. Krames ES, Lanning RM. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage. 1993;8:539-48.
21. Hassenbusch SJ. Cost modeling for alternate routes of administration of opioids for cancer pain. Oncology. 1999;13(5 Suppl 2):63-7. Williston Park.
22. Krames ES. Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. J Pain Symptom Manage. 1996;11:333-52.
23. Hassenbusch SJ, Portenoy RK, Cousins M, Buchser E, Deer TR, Du Pen SL, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage. 2004;27:540-63.
24. Winkelmuller W, Burchiel K, Van Buyten J. Intrathecal opioid therapy for pain: efficacy and outcomes. Neuromodulation. 1999;2:67-76.
25. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol. 2001;55:79-86.
26. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med. 2001;2:287-97.
27. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002;97:803-10.
28. Buchser E, Durrer A, Chedel D, Mustaki JP. Efficacy of intrathecal bupivacaine: how important is the flow rate? Pain Med. 2004;5:248-52.
29. Yaksh TL, Allen JW. The use of intrathecal midazolam in humans: a case study of process. Anesth Analg. 2004;98:1536-45.
30. Willis KD, Doleys DM. The effects of long term intraspinal infusion therapy with noncancer pain patients: evaluation of patient, significant-other, and clinic staff appraisals. Neuromodulation. 1999;2:241-53.
31. Kamran S, Wright BD. Complications of intrathecal drug therapy. Neuromodulation. 2001;4:111-5.
32. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med. 2006;7:251-9.
33. Mironer YE, Tollison CD. Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neruoaxial agents: The first experience. Neuromodulation. 2001;4:25-31.
34. Shir Y, Shapira SS, Shenkman Z, Kaufman B, Magora F. Continuous epidural methadone treatment for cancer pain. Clin J Pain. 1991;7:339-41.
35. Mironer YE, Haasis JC, Chapple ET. Successful use of methadone in neuropathic pain: A multicenter study by the National Forum of Independent Pain clinicians. Pain Digest. 1999;9:191-3.
36. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: A double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation. 2002;5:208-13.
37. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274-8.
38. Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393-406.
39. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63-70.
40. Bergqvist D, Wu CL, Neal JM. Anticoagulation and neuraxial regional anesthesia: perspectives. Reg Anesth Pain Med. 2003;28:163-6.
41. Dickerman RD, Stevens QE, Schneider SJ. The role of surgical placement and pump orientation in intrathecal pump system failure: a technical report. Pediatr Neurosurg. 2003;38:107-9.
42. Harney D, Victor R. Traumatic syrinx after implantation of an intrathecal catheter. Reg Anesth Pain Med. 2004;29:606-9.
43. Huntoon MA, Hurdle MF, Marsh RW, Reeves RK. Intrinsic spinal cord catheter placement: implications of new intractable pain in a patient with a spinal cord injury. Anesth Analg. 2004;99:1763-5.
44. Levin GZ, Tabor DR. Paraplegia secondary to progressive necrotic myelopathy in a patient with an implanted morphine pump. Am J Phys Med Rehabil. 2005;84:193-6.
45. Hassenbusch S, Burchiel K, Coffey RJ, Cousins MJ, Deer T, Hahn MB, et al. Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med. 2002;3:313-23.
46. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery. 2002;50:78-86.
47. Langsam A. A case of spinal cord compression syndrome by a fibrotic mass presenting in a patient with an intrathecal pain management pump system. Pain. 1999;83:97-9.
48. Yaksh TL. Coffey RJ. Spinal opiate toxicity. Proceedings of ASRA conference; 2004 Nov 18-21, Phoenix, AZ, USA.
49. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. Eur J Pain. 2006;10:251-61.
50. Gradert TL, Baze WB, Satterfield WC, Hildebrand KR, Johansen MJ, Hassenbusch SJ. Safety of chronic intrathecal morphine infusion in a sheep model. Anesthesiology. 2003;99:188-98.
51. Yaksh TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, et al. Chronically infused intrathecal morphine in dogs. Anesthesiology. 2003;99:174-87.
52. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med. 2002;3:300-12.
53. Rauck R. Management of Intrathecal Pump Complications. ASRA conference proceedings; 2005 Nov 17-20; Miami, FL; USA.
54. Allen JW, Horais KA, Tozier NA, Wegner K, Corbeil JA, Mattrey RF, et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology. 2006;105:581-9.
55. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996;11:71-80.
56. Gyssens IC. Preventing postoperative infections: current treatment recommendations. Drugs. 1999;57:175-85.
57. Ubogu EE, Lindenberg JR, Werz MA. Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Reg Anesth Pain Med. 2003;28:470-4.
58. Hayek SM, Paige B, Girgis G, Kapural L, Fattouh M, Xu M, et al. Tunneled epidural catheter infections in noncancer pain: increased risk in patients with neuropathic pain/complex regional pain syndrome. Clin J Pain. 2006;22:82-9.
59. Jones TF, Feler CA, Simmons BP, Melton K, Craig AS, Moore WL, et al. Neurologic complications including paralysis after a medication error involving implanted intrathecal catheters. Am J Med. 2002;112:31-6.
60. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215-22.
61. Trang T, Quirion R, Jhamandas K. The spinal basis of opioid tolerance and physical dependence: Involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites. Peptides. 2005;26:1346-55.
62. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000;20:7074-9.
63. Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol. 2000;131:875-84.
64. Wong CS, Chang YC, Yeh CC, Huang GS, Cherng CH. Loss of intrathecal morphine analgesia in terminal cancer patients is associated with high levels of excitatory amino acids in the CSF. Can J Anaesth. 2002;49:561-5.
65. Vanderah TW, Suenaga NM, Ossipov MH, Malan TP Jr, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001;21:279-86.
66. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann N Y Acad Sci. 2001;933:175-84.
67. Melzack R, Coderre TJ, Katz J, Vaccarino AL. Central neuroplasticity and pathological pain. Ann N Y Acad Sci. 2001;933:157-74.